Sign inJoin waitlistJoin the waitlist

Andrew Wagner

Deputy Chief Medical Officer · Mass General Brigham

Credentials: · · · ·

History

Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2003–2006
Hematology and Medical Oncology
Brigham and Women's Hospital
2000–2003
Internal Medicine
Brigham and Women's Hospital
1997–2000
University of Chicago Pritzker School
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1993–1997

Research

The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
Genes & Development · 1997 · 977 citations
Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1
Genes & Development · 1994 · First of 3 authors · 540 citations
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
New England Journal of Medicine · 2015 · 459 citations

WT
William Tap
32 papers
George Demetri
28 papers
Suzanne George
28 papers
Jason Hornick
19 papers
Chandrajit Raut
14 papers
Emanuela Palmerini
14 papers · 8 as a resident
John Healey
14 papers
RM
Robert Maki
13 papers
RJ
Robin Jones
13 papers
JM
Jeffrey Morgan
12 papers
CF
Christopher Fletcher
11 papers
Edwin Choy
11 papers

Clinical trials

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Principal investigator · Active not recruiting · Phase 2
Sarcoma Alliance for Research through Collaboration
2024–2027
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Principal investigator · Completed · Phase 2
Andrew J. Wagner, MD, PhD
2010–2015
Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Prolexys Pharmaceuticals
2007–2011